Expert Analysis

Advances in HCV Treatment: 2006

Source: CCO Independent Conference Coverage of the 2006 Annual Meeting of the American Association for the Study of Liver Diseases*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Advances in HCV Treatment: 2006

Faculty:

Nezam H. Afdhal, MD, FRCPI
Karen L. Lindsay, MD, MMM
Mitchell L. Shiffman, MD

CME CREDIT INFORMATION

Release Date: 12/13/06

Expiration Date: 12/12/07

Physicians: maximum of 1.5 AMA PRA Category 1 Credits™

Registered Nurses: 2.0 Nursing CE credits

Pharmacists: 1.6 contact hours (0.16 CEUs)

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe the results of recent studies of diagnostic tests for viral hepatitis and its complications
Discuss the latest treatments, both approved and experimental, for acute and chronic hepatitis and its complications
Review the epidemiology, pathogenesis, and natural history of acute and chronic hepatitis

Topics covered include:

Telaprevir and Peginterferon alfa-2a Therapy
HCV Polymerase Inhibitors R1626 and HCV-796
Valopicitabine Plus Peginterferon alfa-2b Combination Therapy
Eltrombopag for Treatment of Thrombocytopenia Prior to HCV Therapy
Efficacy and Tolerability of Taribavirin vs Ribavirin Combination Therapy
Genetic Cirrhosis Risk Score to Predict Risk of Fibrosis Progression
Noninvasive Measurements for Identifying Cirrhosis
Treating HCV Patients With High Body Weight
SVR Rates in Hispanic HCV Patients
SVR Rates by Age in the WIN-R Trial
Consensus Interferon Plus Ribavirin for Retreatment of Peginterferon Nonresponders
HCV Treatment Extension to 72 Weeks
Virologic Response at Week 4 and Cumulative Exposure Predict SVR in HCV Genotype 2/3 Patients

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.